Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma  by Krempien, R. et al.
REVIEW ARTICLE
Neoadjuvant chemoradiation in patients with pancreatic
adenocarcinoma
R. KREMPIEN, M. W. MUENTER, W. HARMS & J. DEBUS
Department of Radiation Oncology, University of Heidelberg, Heidelberg, Germany
Abstract
In spite of the high mortality in pancreatic cancer, significant progress is being made. This review discusses multimodality
therapy for patients with pancreatic cancer. Surgical therapy currently offers the only potential monomodal cure for
pancreatic adenocarcinoma. However, only 10/20% of patients present with tumors that are amenable to resection, and
even after resection of localized cancers, long-term survival is rare. The addition of chemoradiation therapy significantly
increases median survival. To achieve long-term success in treating this disease it is therefore increasingly important to
identify effective neoadjuvant/adjuvant multimodality therapies. Preoperative chemoradiation for potentially resectable
pancreatic cancer has the following advantages: (1) neoadjuvant treatment would eliminate the delay of adjuvant treatment
due to postoperative complications; (2) neoadjuvant treatment could avoid unnecessary surgery for patients with metastatic
disease evident on restaging after neoadjuvant therapy; (3) down-staging after neoadjuvant therapy may increase the
likelihood of negative surgical margins; and (4) neoadjuvant treatment could prevent peritoneal tumor cell implantation and
dissemination caused during surgery. This review systematically summarizes the current status, controversies, and prospects
of neoadjuvant treatment of pancreatic cancer.
Introduction
Pancreatic cancer is the fourth commonest cause of
death from cancer in men and women [1,2]. Surgical
therapy currently offers the only potential monomo-
dal cure for pancreatic adenocarcinoma [3]. How-
ever, only a few patients present with tumors that are
amenable to resection, and even after resection of
localized cancers, long-term survival is rare. At
presentation, only 10/20% of patients with pancrea-
tic adenocarcinoma have potentially resectable can-
cers, 40% have locally advanced unresectable
tumors, and 40% have metastatic disease. Adeno-
carcinoma of the pancreas has a 5-year survival rate
of only 4% [2]. In spite of the progress in surgical
treatment, resulting in increased resection rates and
a decrease in treatment-related morbidity and mor-
tality, resection has failed to improve long-term
survival [3]. By histological evaluationB/15% of the
patients undergoing R0 resection have a pN0
status,/50% suffer from lymphangiosis carcinoma-
tosa, and/50% suffer from extrapancreatic nerve
plexus infiltration [4,5].
Achievements of surgery
Although surgery offers a low cure rate, it is also the
only chance for cure. Regarding long-term survival
after R0 resection, only 3/16% of the patients from
selected series survived 5 years or more. Locoregional
recurrence and/or metastatic disease develop in the
majority of patients who undergo pancreatic resec-
tion. Relapse occurs within 9/15 months after initial
presentation and patients have median life expectan-
cies of only 12/15 months without adjuvant therapy.
The 5-year survival rate of patients with resected
pancreatic adenocarcinoma is approximately 10% [3].
The statistics for the 80/90% of patients who present
with locally advanced and metastatic pancreatic
cancer are even more dismal. Rarely do such patients
achieve a complete response to treatment; median
survival is 5/10 months and 5-year survival is near
zero [6].
The cardinal rule in improving the prognosis in
patients with pancreatic cancer proved to be complete
tumor removal in patients undergoing oncological
resection [3,4]. In most recent published prospective
trials, R0 resection results in an increase of survival in
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comparison with patients with a residual tumor [7,8].
However, R0 resection fails to improve long-term
survival [4]. More than 95% of the patients under-
going surgical resection are at an advanced stage of
cancer. Potentially curative resection is hampered by a
failure to include remote cancer cell-positive tissues in
the operative specimen, i.e. N2 lymph nodes, nerve
plexus, and perivascular tissue [9,10]. Cancer recur-
rence after resection with curative intent is the
consequence of cancer cell-positive tissues left behind.
However, comparison of the survival times after
standard and extended resection of pancreatic cancers
indicated that no significant long-term survival benefit
resulted from extended R0 resection [11,12].
Dissemination pattern of pancreatic cancer
Using molecular biological methods like reverse
transcriptase polymerase chain reaction (RT-PCR)
or immunostaining, a new dimension of micrometas-
tasis has been objectified. With the higher sensitivity
of these molecular biological methods, up to 60% of
lymph nodes previously seen as microscopically free of
cancer showed micrometastasis by RT-PCR even in
UICC stage I or II cancers [5,13]. Nerve plexus
invasion outside of the pancreas has been observed in
43/72% of patients [14,15]. Further, careful histo-
pathological evaluation of cancer dissemination has
demonstrated that even in stage I and II cancers,
lymph vessels surrounding the pancreas are cancer
cell infiltrated in most of the cases [5,14]. In bone
marrow specimens micrometastasis was found in
36/63% of the patients investigated [15]. Among
patients in cancer stage UICC I and II undergoing
surgery, 46% had positive immunostaining for cancer
cells in the bone marrow [16]. Using RT-PCR
techniques 13 of 17 investigated patients showed
micrometastases in the liver; some but not all of these
patients later developed metastatic liver disease
macroscopically [17].
This knowledge about cancer cell dissemination
early in the course of pancreatic cancer, including
early stage cancers, explains why true R0 resection in
pancreatic cancer is difficult to achieve, and explains
the observed frequency of recurrence in /95% of
patients undergoing surgical resection with curative
intent.
Combined modality treatment
Both distant and local/regional patterns of recurrence
are common, and this suggests that most patients have
occult metastatic or local/regional disease (or both) at
the time of resection. According to several phase II or
III trials, combined modality treatment approaches
using chemotherapy or chemoradiation in addition to
surgery can achieve improvement in locoregional
control and survival.
Postoperative chemoradiation therapy (CRT) has
been shown to improve survival in patients with
resected pancreatic adenocarcinoma [7,18,19],
although there is debate over whether radiotherapy
is a beneficial component [8]. The problems with the
postoperative adjuvant approach include the fact that
at least 25% of patients do not actually receive
adjuvant therapy because of complications of surgery
or patient refusal [7,20]. A primary advantage of
preoperative therapy is therefore the assurance that
CRT is received by all patients with resected disease
in a timely fashion. Other benefits are the delivery of
radiation to well-oxygenated tissues and the avoidance
of radiation to fixed loops of intestine within the
operative field. Another rationale for neoadjuvant
treatment is that occult metastatic disease is given
the opportunity to manifest, thus allowing patients to
avoid the morbidity of resection or laparotomy.
Finally, the potential for preoperative CRT to convert
locally advanced lesions to resectable lesions could
greatly increase the number of patients with pancrea-
tic cancer who might be offered a chance of cure [21].
To achieve long-term success in treating this
disease it is therefore increasingly important to
identify effective neoadjuvant/adjuvant multimodality
therapies.
Neoadjuvant treatment for pancreatic cancer
The goal of neoadjuvant treatment is down-staging
and, in combination with an oncological resection,
increasing the chances of survival [22]. Since R0
resection is a prerequisite for cure, the aim of any
multimodal treatment should be to improve the R0
resection rate. A protocol for neoadjuvant, multi-
modal treatment of pancreatic cancer is not yet
established. Results from uncontrolled prospective
mono-institutional series applying chemoradiation to
patients with pancreatic cancer stage II and III
(UICC) resulted in down-staging in 15/30% of the
patients and a resection rate of the down-staged
patients between 50% and 83%. The median survival
of these patients ranged between 15 and 32 months
(Table I).
In a case control study Ishikawa et al. [23] found
that neoadjuvant chemoradiation led to down-staging
of pancreatic cancers and to the possibility of onco-
logic resection in 17 of 23 patients. Evans et al. [24]
and Hoffmann et al. [25] have pioneered preoperative
chemoradiation for pancreatic cancer. In the initial
preoperative trial, reported by Evans, 28 patients with
cytologic or histologic proof of localized adenocarci-
noma of the pancreatic head received preoperative
radiation (50.4 Gy) and concurrent continuous infu-
sion (CI) of 5-FU 300 mg/m2/day. Patients were
restaged 4/5 weeks after completion of chemoradia-
tion. Five patients were found to have metastasis, and
23 patients without evidence of disease progression
underwent laparotomy. At laparotomy, 3 patients
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were found to have metastasis, 3 patients had un-
resectable locally advanced disease, and 17 patients
underwent pancreaticoduodenectomy. This study
showed that tumor resection could be performed
with a low incidence of complications after chemor-
adiation in patients with pancreatic cancer.
In a pilot study by Hoffman et al. [25], patients
received preoperative CI 5-FU (1000 mg/m2/day on
days 2 to 5 and 29 to 32), mitomycin-C (10 mg/m2/
day on day 2), and radiation (50.4 Gy). For patients
with curative resection, the median survival (from the
time of tissue diagnosis) was 45 months, with a
median disease-free survival of 27 months. Based on
these encouraging results, the ECOG conducted a
trial testing this regime [26]. Of 53 patients, 12 did
not proceed to surgery because of inter-current ill-
ness, toxicity, local progression, distant metastasis, or
death. Seventeen patients underwent surgical explora-
tion but could not be resected because of unresectable
locally advanced disease or distant metastasis.
Twenty-four patients showed down-staging and un-
derwent resection with a median survival of 15.7
months compared with 9.7 months for the entire
group.
So far two studies showed exceptional median
survival rates of 31 and 32 months, respectively.
Snady et al. [27] reported a median survival of
32 months in 20 patients (29%) who had resection
from an original group of 68 patients treated with
neoadjuvant with concurrent split course radiation
therapy and 5-FU, streptozotocin and cisplation. The
median survival of the whole group was 23.6 months,
and 32 months in the resected patients. During the
same period another group of 91 patients underwent
resection, of whom 63 received adjuvant chemother-
apy or chemoradiation. The median survival in
patients who had oncological resection and adjuvant
treatment was 16 months, compared with 11 months
in those that did not have adjuvant treatment after
resection. The median survival of the neoadjuvant-
treated group was significantly better than in the
initially operated group (32 months vs 14 months,
p/0.006). Metha et al. [28] recently reported a
median survival of 30 months with neoadjuvant
treatment but only in nine patients.
Pisters et al. [29] evaluated preoperative rapid-
fractionation chemoradiation in a phase II trial of
35 patients. The preoperative chemoradiation con-
sisted of a 2-week course of 5-fluorouracil (5-FU;
300 mg/m2/day, 5 days per week) and concurrent
radiotherapy (30 Gy over 2 weeks, 3 Gy per fraction).
Following resection patients received intraoperative
radiation therapy (10/15 Gy). Median survival for
patients was 25 months, and 3-year actuarial overall
survival rate was 23%.
Recently, initial results of preoperative gemcitabine-
based chemoradiation for resectable pancreatic cancer
were reported [30]: 86 patients received seven weekly
infusions of gemcitabine 400 mg/m2 on concurrent
radiation therapy (30 Gy over 2 weeks with 3 Gy per
fraction). Patients underwent restaging 4/6 weeks
after the last dose of gemcitabine. Of the 83 patients,
12 (14%) did not undergo surgery. Of the 71 patients
undergoing laparotomy, 10 (12%) were found to have
metastatic disease. Thus 61 patients (73%) under-
went complete resection. Another trial [31] using
gemcitabine applied 50.4 Gy in 28 fractions neoadju-
vant with concomitant twice-weekly gemcitabine
(50 mg/m2) in locally advanced potentially resectable
pancreatic cancers. Of the total of 34 patients, 21
underwent surgery. In the group of resected patients
the estimated median survival was 25 months. Calvo
et al. [32] evaluated neoadjuvant chemoradiation
(total dose of 45/50.4 Gy with daily fractions of
1.8 Gy) with tegafur in potentially resectable pan-
creatic cancers. The tegafur dose was 1200 mg/day
Table I. Neoadjuvant treatment for pancreatic adenocarcinoma.
Reference Year n Neoadjuvant therapy Resection rate Median survival, all
patients (months)
Median survival, resected
patients (months)
Evans et al. [24] 1992 28 EBRT-5-FU (9/IORT) 17/28 (61%) NR NR
Ishikawa et al. [23] 1994 23 EBRT 17/23 (74%) NR NR
Coia et al. [33] 1994 27 EBRT/5-FU/MMC 13/27 (48%) 19% (3-yr SR) 43% (3-yr SR)
Staley et al. [53] 1996 39 EBRT/IORT/5-FU 39/39 (100%) 19 kA
Spitz et al. [54] 1997 91 EBRT/5-FU (9/IORT) 41/91 (45%) 19 19.2
Hoffman et al. [26] 1998 53 EBRT/5-FU/Mit 24/53 (45%)] 9.7 15.7
White et al. [34] 2001 111 EBRT/5-FU/MMC/Cis 39/111 (35%) NR NR
Wanebo et al. [35] 2000 14 EBRT/5-FU/Cis 9/14 (64%) 9 19
Snady et al. [27] 2000 68 EBRT/5-FU/Cis/Strep 20/68 (29%) 23.6 32.3
Metha et al. [28] 2001 15 EBRT/5-FU 9/15 (60%) NR 30
Wilkowski et al. [36] 2003 33 EBRT/Cis/Gem 11/33 (48%) 10 11.7
Magnin et al. [54] 2003 32 EBRT/5-FU/Cis 19/32 (59%) 37.2% (2-yr SR) 59.3% (2-yr SR)
Aristu et al. [55] 2003 47 EBRT/CHT 9 (19%) 10 23
Calvo et al. [32] 2004 15 EBRT/tegafur 9 (60%) 17 23
Joensuu et al. [31] 2004 34 EBRT/Gem 21 (60%) NR 25
CHT,; Cis, cisplatin; EBRT, external beam radiation therapy; 5-FU, 5-fluorouracil; Gem, gemcitabine; IORT, intraoperative radiation
therapy; Mit, mitomycin-C; MMC, mitomycin-C; NR,; Strep, streptozotocin.
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along the external beam radiation therapy (EBRT)
period. Of the 15 enrolled patients a total of 9 patients
underwent surgery. Median survival of the resected
patients was 23 months (completely resected patients
28 months) compared with 8 months in the unre-
sected patients.
Impact of neoadjuvant treatment for potentially
resectable pancreatic cancer
Preoperative chemoradiation for potentially resectable
pancreatic cancer has the following advantages: (1)
neoadjuvant treatment would eliminate the delay of
adjuvant treatment from postoperative recovery; (2)
neoadjuvant treatment could spare unnecessary sur-
gery for patients with metastatic disease evident on
restaging after neoadjuvant therapy; (3) down-staging
after neoadjuvant therapy may increase the likelihood
of negative surgical margins; and (4) neoadjuvant
treatment could prevent peritoneal tumor cell im-
plantation and dissemination during surgery. In
recent controlled clinical trials comparing historical
and prospective control groups, the frequency of
down-staging was observed to be between 13% and
45%. Neoadjuvant chemoradiation resulted in a
decrease in the frequency of cancer-positive margins.
Oncological resection after neoadjuvant chemoradia-
tion resulted in a median survival between 15 and
32 months. During neoadjuvant therapy, disease
progression occurs in 15/25% of the patients, with
the appearance of liver metastases and/or peritoneal
carcinosis. These patients are spared unnecessary
operation. After neoadjuvant treatment no increase
of postoperative complications has been reported.
Unfortunately, many reports of neoadjuvant therapy
for pancreatic cancer have included heterogeneous
patient populations, enrolling patients with resectable,
marginally resectable and locally advanced pancreatic
cancer (Table I) [26,28,31,33/36]. This confounds
reports of resection rates and complicates comparison
with other studies. Therein lies the importance of
using accurate, reproducible anatomic definitions for
resectability.
Impact of neoadjuvant treatment for locally
advanced pancreatic cancer
Because surgical resection of the primary tumor
remains the only potentially curative treatment for
pancreatic cancer, preoperative chemoradiation has
been investigated in locally advanced pancreatic
cancer to down-stage locoregional disease to facilitate
surgical resection and to improve the rate of complete
(R0) resections. Locally advanced pancreatic cancer
describes pancreatic cancer without evidence of dis-
tant metastasis but unresectable situation because of
tumor encasement of major vessel structures such as
celiac and superior mesenteric arteries or adherence
to the portal vein. Down-staging in this group of
locally advanced pancreatic cancer leads to a separa-
tion between tumor and vessel wall and to an increase
of resection rates between 29% and 80%, and a
survival benefit after oncological resection (Table I).
In evaluating the results of multimodality ap-
proaches in locally advanced pancreatic cancer, it is
useful to remember that a median survival of
3/6 months has been reported for this subset of
patients undergoing palliative gastric or biliary bypass
only [37].
Despite the potential benefits for patients with
locally advanced pancreatic cancer receiving chemor-
adiation, those gains are modest. Rarely do such
patients achieve a complete response to treatment.
In cases where no down-staging with secondary
resectability can be achieved, median survival is
around 10 months and 5-year survival is near zero
[6]. Despite this, significant palliative benefit can be
achieved by chemoradiation. Complete pain relief
can be obtained in as many as 50/80% of patients,
as well as some improvement in wasting, obstructive
symptoms, performance status, and anorexic symp-
toms [38].
Although local control rates have been improved by
radiation therapy, systemic failure remains a major
obstacle in improving the long-term survivorship.
Because of the high rates of distant metastasis and
poor overall survival results, the value of secondary
resection after conversion of unresectable disease to
resectable disease is questioned in the treatment of
this subgroup. As this issues have so far not been
addressed in larger published studies the question
remains controversial. Regarding the available smaller
phase I and II studies (Table I), secondary resect-
ability results in median survival between 15% and
32% compared with 9/20% for all patients. As
these are only small, mostly nonrandomized, single
institution studies they may be subject to selection
bias. Following neoadjuvant therapy the patient
undergoes restaging (usually several months after
the initial diagnosis) and patients who have developed
interval metastases are excluded. Further interpreta-
tion of these data is difficult because of different
criteria for resectability. The reported resection
rates vary between 45% and 100% in patients with
tumors initially deemed resectable and from 29% to
80% in those with unresectable disease (Table I),
indicating that primary resectability has been defined
differently. A specialist pancreatic cancer surgery
team can often resect what is considered by another
team to be unresectable locally advanced disease.
For example, the Johns Hopkins group was able to
carry out resection on 52 of 78 patients (67%)
operated upon elsewhere and thought to have irre-
sectable disease [39]. For future trials, it will be
important to identify patients with locally advanced
cancer as a unique subset requiring careful diagnostic
work-up and definition of common resectability
criteria.
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Radiation therapy dose escalation
Several trials could show that dose escalation in
radiation therapy using either external beam radiation
therapy (EBRT) [18] or intraoperative radiation
therapy (IORT) [40,41] resulted in improved local
control in combination with potentially curative
resection. The efficacy of EBRT in pancreatic cancer
is limited by the inability to deliver adequate doses of
irradiation secondary to the dose tolerance limits of
small bowel, spinal cord, stomach, kidney, and liver.
Further, the use of combined modality approaches
in pancreatic cancer is associated with increased
gastrointestinal toxicity. Technical developments like
intensity-modulated radiation therapy (IMRT) have
the potential to significantly improve radiation
therapy of pancreatic cancers by reducing normal
tissue dose, and simultaneously allow escalation of
dose to further enhance locoregional control [42].
Future directions in neoadjuvant therapy
Currently perhaps the most poorly defined parameter
in the treatment of pancreatic cancer is patient
selection for therapy. Whereas in other cancers
assessment of aberrations in gene expression that
correspond with therapeutic response and outcome
are being adopted routinely to increase predictive
power (e.g. HER-2/neu in breast cancer), there are
only preliminary data on molecular markers of clinical
utility in pancreatic cancer. A bewildering number of
biomarkers are currently under evaluation [43,44].
For the most part, the evidence regarding their
application as prognostic indicators is conflicting.
Current choice of therapy is based on histopatho-
logic assessment of the tumor. Recent advances in
molecular biology have provided a detailed under-
standing of molecular events in pancreatic carcino-
genesis and may offer new approaches to the
treatment of pancreatic cancer [45]. The develop-
ment, progression, and metastasis of pancreatic can-
cer are determined by accumulation of multiple
genetic and epigenetic changes, including inactivation
of tumor suppressor genes and overexpression of
proto-oncogenes [46].
In recent years, chemoradiation has evolved as the
standard treatment for locally advanced pancreatic
carcinoma. The rationale for concurrent administra-
tion of chemotherapy is to improve locoregional
control by sensitizing the tumor for radiotherapy
(radiosensitization), and to treat potential distant
micrometastases. Recently, new biological treatment
options have emerged that target specific pathways of
either tumor cells or normal cells within the tumors
[21,47].
New therapeutic strategies exploit a critical func-
tion or genetic abnormality of cancers. These strate-
gies are directed at key proteins or genes responsible
for various aspects of cell proliferation, differentiation
and function, as well as angiogenesis and invasion
[46/48]. For example, there are various tyrosine
kinase-dependent pathways of great interest in the
treatment of pancreatic cancer. The epidermal growth
factor receptor (EGFR) is involved in such carcino-
genic cellular processes as invasion, metastasis, angio-
genesis, and radiation resistance [48,49]. In a recently
completed phase II trial the monoclonal EGFR anti-
body cetuximab in combination with gemcitabine for
patients with advanced pancreatic cancer showed
considerably better results than those achieved using
gemcitabine alone as documented in a previous phase
III trial [50]. Recently a phase III study could
demonstrate the benefit of the combination of an
EGFR tyrosine kinase inhibitor in combination with
chemotherapy in pancreatic cancer [51]. A total of
569 patients with advanced pancreatic cancer were
randomized to receive standard dose gemcitabine,
1000 mg/m2 i.v. weekly in 7 of 8 weeks, then weekly
in 3 of 4 weeks plus either erlotinib 100 mg daily
(n/285) or placebo (n/284). Combined erlotinib
therapy with gemcitabine resulted in a 24% improve-
ment in survival as compared with placebo (p/0.025)
with corresponding 1-year survival rates of 24% and
17% (erlotinib and placebo arm, respectively). Also,
vascular endothelial growth factor (VEGF) receptor
inhibitors or platelet-derived growth factor (PDGF)
receptor inhibitors are currently being tested in
combination with other cytotoxic drugs in pancreatic
cancers [45,46].
Treatment-related primary and acquired chemo-
radioresistance presents a significant hindrance for all
current therapy regimes in pancreatic cancer patients
[23,24]. Multiple factors such as genetic instability of
tumors and high inter- and intra-tumoral heterogene-
ity contribute to the hardly predictable therapy
resistance [22]. Understanding of patterns of therapy
response genome expression profiling and detection of
genetic polymorphisms will enable researchers to
identify key mechanisms in systems biology.
Conclusion
Pancreatic cancer remains one of the most formidable
challenges in oncology. The length and quality of life
will be maximized by accurate preoperative staging,
assessment of resectability, and the use of protocol-
based multimodality treatments. Surgical therapy
currently offers the only potential monomodal cure
for pancreatic adenocarcinoma. However, only a few
patients present with tumors that are amenable to
resection, and even after resection of localized can-
cers, long-term survival is rare. Therefore surgery
should always be performed as part of a multimodality
approach involving neoadjuvant and/or adjuvant
treatment. Continued efforts to enroll patients into
well designed clinical trials should remain a high
priority for oncologists across all disciplines. For
future trails, it will be important to identify patients
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with primary irresectable, locally advanced pancreatic
cancer as a unique subset requiring careful diagnostic
work-up and definition of common resectability
criteria.
Currently perhaps the most poorly defined para-
meter in the treatment of pancreatic cancer is patient
selection for therapy. The objectives of future studies
are to correlate and potentially predict therapy re-
sponse using tumor genomic fingerprints. Significant
improvements in long-term survival will likely be
achieved through exploitation of the basic biologic
anomalies of this malignancy. Recently, new biological
treatment options have emerged that target specific
pathways of either tumor cells or normal cells within
the tumors. These strategies are directed at key
proteins or genes responsible for various aspects of
cell proliferation, differentiation and function, as well
as angiogenesis and invasion.
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